scholarly journals 2015 Guidance on cancer immunotherapy development in early‐phase clinical studies

2015 ◽  
Vol 106 (12) ◽  
pp. 1761-1771 ◽  
Author(s):  
◽  
Teruyo Arato ◽  
Takashi Daimon ◽  
Yuji Heike ◽  
Ken Ishii ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Clinical Studies ◽  
Early Phase

Extemporaneous preparation strategy for early phase clinical studies

2018 ◽  
Vol 549 (1-2) ◽  
pp. 150-160 ◽  
Author(s):  
Rampurna P. Gullapalli ◽  
Carolyn L. Mazzitelli ◽  
Christina M. Charriez ◽  
David J. Carpenter ◽  
Rebecca D. Crean ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Early Phase ◽  
Extemporaneous Preparation ◽  
Preparation Strategy

Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia

2014 ◽  
Vol 8 (1) ◽  
pp. 29-49 ◽  
Author(s):  
Brett A English ◽  
Kelan Thomas ◽  
Jack Johnstone ◽  
Adam Bazih ◽  
Lev Gertsik ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Early Phase ◽  
Pharmacodynamic Biomarkers

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis

2017 ◽  
Vol 55 ◽  
pp. 10-15 ◽  
Author(s):  
R. Costa ◽  
N. Gill ◽  
A.W. Rademaker ◽  
B.A. Carneiro ◽  
Y.K. Chae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Clinical Studies ◽  
Early Phase ◽  
Systematic Analysis

scholarly journals Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Gang Zhou ◽  
Hyam Levitsky
Keyword(s):  
Cancer Immunotherapy ◽  
Tumor Cells ◽  
Clinical Studies ◽  
Cytotoxic T Lymphocyte ◽  
Treatment Strategies ◽  
Therapeutic Modality ◽  
Tumor Escape ◽  
Immune Effector ◽  
Therapeutic Outcomes ◽  
Preclinical And Clinical Studies

The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) ipilimumab for advanced melanoma. In addition, the clinical evaluations of a variety of promising immunotherapy drugs are well under way. Benefiting from more efficacious immunotherapeutic agents and treatment strategies, a number of recent clinical studies have achieved unprecedented therapeutic outcomes in some patients with certain types of cancers. Despite these advances, however, the efficacy of most cancer immunotherapies currently under clinical development has been modest. A recurring scenario is that therapeutic maneuvers initially led to measurable antitumor immune responses in cancer patients but ultimately failed to improve patient outcomes. It is increasingly recognized that tumor cells can antagonize therapy-induced immune attacks through a variety of counterregulation mechanisms, which represent a fundamental barrier to the success of cancer immunotherapy. Herein we summarize the findings from some recent preclinical and clinical studies, focusing on how tumor cells advance their survival and expansion by hijacking therapy-induced immune effector mechanisms that would otherwise mediate their destruction.

Sign in / Sign up

Export Citation Format

Share Document